



Appendix 4

List of participating organisations in SISAQOL-IMI by stakeholder group

Patients' representative (n = 1)
Myeloma Patients Europe (on behalf of the Workgroup of European Cancer Advocacy Networks - WECAN)
Academic institutions (n = 17)
Clinical Hospital Center Rijeka, Croatia
Complejo Hospitalario de Navarra, Spain
Duke University School of Medicine, USA
Institut Hospital del Mar d'Investigacions Mèdiques, Spain
John Hopkins University, USA
Katholieke Universiteit Leuven, Belgium
Leiden University Medical Center, Germany
MD Anderson Cancer Center, University of Texas, USA
Medical University of Innsbruck, Austria
Oslo University Hospital, Norway
Region Hovedstaden, Denmark
University Health Network, Canada
University of Birmingham, UK
University of Freiburg, Germany
University of Ghent, Belgium
University of Leeds, UK
Amsterdam University Medical Center, the Netherlands

Non-profit/Cancer organizations (n = 8)
American Society for Clinical Oncology, USA
Critical Path Institute, USA
European Organisation for Research and Treatment of Cancer, Belgium
European Society for Medical Oncology, Switzerland
National Cancer Center Hospital (Japan Clinical Oncology Group), Japan
National Cancer Institute, USA
Queen's University at Kingston (CCTG), Canada
University of Sydney (Sydney Quality of Life Office), Australia
Regulatory (n =4)
European Medicines Agency, The Netherlands
Health Canada, Canada
Medicines and Healthcare products Regulatory Agency, UK
US Food and Drug Administration, USA
Health technology assessment (HTA) (n= 2)
Institute for Quality and Efficiency in Health Care, Germany
Norwegian Medicines Agency, Norway
Industry (n = 5)
AbbVie, USA
Bayer, Germany
Boehringer Ingelheim, Germany
Merck, Germany
Pfizer, USA
Small to mid-size enterprise (SME)/Contract research organization (CRO)(n = 4)
Adelphi Values, UK
Evaluation Software Development, Austria
Modus Outcomes, France
Patient Relevant Evidence, USA